---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-080012"
form_type: "8-K"
ticker: "ELOX"
cik: "0001035354"
company_name: "Eloxx Pharmaceuticals, Inc."
filed_at: "2022-07-15T23:59:59+00:00"
generated_at: "2026-06-24T13:52:35.814669+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Eloxx Pharmaceuticals dismisses Deloitte, appoints Baker Tilly as auditor; no disagreements reported

## Summary
- Deloitte & Touche dismissed as independent auditor; Baker Tilly US, LLP engaged for FY 2022, effective July 13, 2022.
- No disagreements or reportable events between Eloxx and Deloitte during 2020, 2021, or through July 13, 2022.
- Deloitte's audit reports for FY 2020 and 2021 included a going concern doubt about the company's ability to continue.
- Deloitte confirmed agreement with the disclosures in a letter filed as Exhibit 16.1; no prior consultations with Baker Tilly.

## SEC filing metadata
- accession: 0001104659-22-080012
- form_type: 8-K
- ticker: ELOX
- cik: 0001035354
- company_name: Eloxx Pharmaceuticals, Inc.
- filed_at: 2022-07-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 4.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1035354/000110465922080012/0001104659-22-080012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1035354/000110465922080012/tm2221060d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-080012
- JSON: https://secwatch.observer/filing/0001104659-22-080012.json
- Plain text: https://secwatch.observer/filing/0001104659-22-080012.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.